| Property |
Value |
| Category |
Neuronal Growth/Regeneration Marker |
| Target |
Growth-Associated Protein 43 |
| Sample Type |
CSF, brain tissue, plasma |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, Stroke, Traumatic Brain Injury, ALS |
| Sensitivity |
Moderate |
| Specificity |
High for neuronal sprouting |
Growth-Associated Protein 43 (GAP-43), also known as neuromodulin, is a neuronal phosphoprotein specifically expressed in developing and regenerating neurons. GAP-43 plays a critical role in axonal growth, synaptic plasticity, and nerve regeneration. As a biomarker, GAP-43 provides unique insights into neuronal repair mechanisms and synaptic remodeling in neurodegenerative diseases and CNS injury.
GAP-43 is encoded by the GAP43 gene (chromosome 3q13.31), a highly conserved protein across species. The 238-amino acid protein has a molecular weight of 24-26 kDa and contains:
- Calmodulin-binding domain
- Protein kinase C (PKC) phosphorylation site
- Palmitoylation sites for membrane anchoring
- Axonal targeting sequences
- Developmental CNS: High expression during neuronal differentiation and axonal pathfinding
- Adult brain: Low baseline expression, restricted to:
- Hippocampal formation (CA3, dentate gyrus)
- Cerebral cortex (layer II-IV)
- Basal forebrain cholinergic neurons
- Locus coeruleus
- Regeneration response: Rapid upregulation after injury
GAP-43 is a sensitive marker for:
- Stroke: Elevated CSF GAP-43 correlates with infarct size and functional outcome
- Traumatic Brain Injury (TBI): CSF GAP-43 predicts recovery trajectory
- Spinal cord injury: Tissue GAP-43 indicates regenerative potential
- Reduced hippocampal GAP-43 correlates with memory impairment
- CSF GAP-43: elevated in early AD, reflects synaptic remodeling attempts
- Therapeutic implications: GAP-43 enhancement strategies
- Reduced GAP-43 in substantia nigra
- Correlates with dopaminergic neuron loss
- Potential for monitoring neuroprotective therapies
- Elevated CSF GAP-43 in early disease stages
- Reflects attempted axonal regeneration
- Correlates with disease progression rate
- Schizophrenia: Altered GAP-43 in prefrontal cortex
- Depression: Reduced hippocampal GAP-43
- Addiction: Changes in reward circuitry GAP-43
| Method |
Sample |
Sensitivity |
| ELISA |
CSF, plasma |
pg/mL range |
| Western Blot |
Tissue, CSF |
Qualitative |
| Immunohistochemistry |
Tissue |
Visual |
| SIMOA |
CSF |
Ultra-sensitive |
¶ Stroke and TBI
- Prognostic biomarker: Higher early GAP-43 predicts better recovery
- Therapeutic monitoring: Response to rehabilitation and neuroprotective drugs
- Outcome prediction: Correlates with modified Rankin Scale at 3-6 months
- Early detection: Changes precede clinical symptoms
- Disease progression: Longitudinal tracking of neuronal integrity
- Therapeutic efficacy: Response to disease-modifying treatments
GAP-43 serves as:
- Pharmacodynamic biomarker for neurorestorative drugs
- Patient stratification marker
- Surrogate endpoint for regenerative therapies
- PKC modulators: Increase GAP-43 phosphorylation
- cAMP enhancers: Upregulate GAP-43 expression
- mTOR inhibitors: Promote axonal regeneration (paired with GAP-43 monitoring)
- Nogo receptor blockers: Enhance regenerative response
| Biomarker |
What it Measures |
Combination Benefit |
| GAP-43 |
Neuronal sprouting |
Regeneration assessment |
| NfL |
Axonal degeneration |
Damage quantification |
| Neurogranin |
Synaptic integrity |
Complete picture |
The study of Gap 43 Neuronal Regeneration Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Benowitz LI, et al. (1989). The growth-associated protein GAP-43: a novel polypeptide that is redistributed when PC12 cells are treated with NGF. J Cell Biol. 108(5): 1801-1812. PMID:2523898
- Skene JH, et al. (1989). GAP-43 as a marker for CNS neuronal development. Prog Brain Res. 82: 33-39. PMID:2560666
- De la Monte SM, et al. (1989). Selective accumulation of GAP-43 protein in Alzheimer's disease brain. J Neurosci Res. 23(1): 89-95. PMID:2568423
- Masliah E, et al. (1991). Patterns of GAP-43 immunoreactivity in Alzheimer's disease. J Neural Transm Suppl. 33: 133-143. PMID:1856895
- VanGuilder HD, et al. (2011). Elevated GAP-43 in Alzheimer's disease and mild cognitive impairment. J Neurochem. 118(4): 563-569. PMID:21320193
- Hattiangady B, et al. (2014). Neural stem cell grafting counteracts age-related mitochondrial abnormalities in mouse hippocampus. Neurobiol Aging. 35(10): 2149-2165. PMID:24786631
- Strohm R, et al. (2019). Growth-associated protein 43 (GAP-43) in cerebrospinal fluid after stroke. J Neurol Sci. 407: 116457. PMID:31077888
- Ziu M, et al. (2016). Temporal profile and clinical significance of serum and CSF GAP-43 levels after acute brain injury. Neurol Sci. 37(7): 1101-1107. PMID:26993162